National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland, USA.
US Public Health Service, Rockville, Maryland, USA.
Clin Infect Dis. 2022 Aug 24;75(1):e201-e207. doi: 10.1093/cid/ciab952.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus testing among first responders and healthcare personnel who participated in a May 2020-August 2020 serosurvey that assessed spike protein antibodies provided an opportunity to assess reinfection.
Serology survey data were merged with virus testing results from Rhode Island (1 March 2020-17 February 2021) and New York City (10 March 2020-14 December 2020). Participants with a positive virus test ≥14 days before their serology test were included. Reinfection was defined as a second positive SARS-CoV-2 test ≥90 days after the first positive test. The association between serostatus and reinfection was assessed with a proportional hazards model.
Among 1572 previously infected persons, 40 (2.5%) were reinfected. Reinfection differed by serostatus: 8.4% among seronegative vs 1.9% among seropositive participants (P < .0001). Most reinfections occurred among Rhode Island nursing home and corrections personnel (n = 30) who were most frequently tested (mean 30.3 tests vs 4.6 for other Rhode Island and 2.3 for New York City participants). The adjusted hazard ratio (aHR) for reinfection in seropositive vs seronegative persons was 0.41 (95% confidence interval [CI], .20-.81). Exposure to a household member with coronavirus disease 2019 (COVID-19) before the serosurvey was also protective (aHR, 0.34; 95% CI, .13-.89).
Reinfections were uncommon among previously infected persons over a 9-month period that preceded widespread variant circulation. Seropositivity decreased reinfection risk. Lower reinfection risk associated with exposure to a household member with COVID-19 may reflect subsequently reduced household transmission.
对 2020 年 5 月至 8 月参加血清学调查的急救人员和医护人员进行了严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)病毒检测,该调查评估了刺突蛋白抗体,为评估再感染提供了机会。
血清学调查数据与罗德岛(2020 年 3 月 1 日至 2021 年 2 月 17 日)和纽约市(2020 年 3 月 10 日至 2020 年 12 月 14 日)的病毒检测结果合并。包括血清学检测前 14 天内病毒检测阳性的参与者。将第二次 SARS-CoV-2 检测阳性且间隔首次检测阳性 90 天以上定义为再感染。采用比例风险模型评估血清学状态与再感染的相关性。
在 1572 例既往感染者中,有 40 例(2.5%)发生再感染。再感染率因血清学状态而异:血清阴性者为 8.4%,血清阳性者为 1.9%(P<0.0001)。大多数再感染发生在罗德岛疗养院和惩教人员中(30 例),他们接受了最频繁的检测(平均检测 30.3 次,而罗德岛其他参与者为 4.6 次,纽约市参与者为 2.3 次)。血清阳性者与血清阴性者相比,再感染的调整后风险比(aHR)为 0.41(95%置信区间 [CI],0.20-0.81)。血清学调查前与新型冠状病毒肺炎(COVID-19)患者接触的家庭成员也具有保护作用(aHR,0.34;95%CI,0.13-0.89)。
在广泛传播变异株之前的 9 个月期间,既往感染者再感染并不常见。血清阳性降低了再感染的风险。与 COVID-19 患者家庭成员接触后再感染风险降低可能反映了随后家庭传播减少。